Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings Inc. (NASDAQ: BFRG) is a biotechnology innovator using artificial intelligence to accelerate drug discovery and clinical development. This news hub provides investors and industry professionals with timely updates on the company's AI-driven research initiatives, strategic partnerships, and therapeutic advancements.
Access consolidated information on BFRG's latest press releases including clinical trial progress, regulatory milestones, and technology developments related to its proprietary bfLEAP platform. Our curated collection serves as an essential resource for tracking advancements in precision medicine and AI-powered pharmaceutical research.
Key updates cover therapeutic focus areas such as liver disease treatments, obesity research, and neuropsychiatric disorder solutions. Stay informed about collaborative projects with leading research institutions and data-driven breakthroughs in biomarker discovery.
Bookmark this page for direct access to BullFrog AI's official announcements and third-party analysis. Regularly updated content ensures you maintain current awareness of the company's position at the intersection of biotechnology and artificial intelligence innovation.
BullFrog AI (NASDAQ: BFRG; BFRGW) has appointed Dr. John Baldoni to its Scientific Advisory Board. Dr. Baldoni brings over 40 years of pharmaceutical industry experience, including 29 years in R&D at GSK where he served as Senior Vice President of Platform and Technology Sciences. He is the co-founder of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium and former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare.
Vin Singh, CEO of BullFrog AI, stated that Dr. Baldoni's experience in pharmaceutical R&D and leadership in technology-driven drug discovery will provide valuable insights for the commercialization of their bfLEAP™ platform. Dr. Baldoni expressed excitement about collaborating with BullFrog AI, recognizing the potential of the bfLEAP™ platform to transform complex biological data analysis in drug discovery and development.
BullFrog AI Holdings (NASDAQ: BFRG) announced new research supporting the potential of its drug candidate BF-114 in treating liver diseases. The study, published in Cell Reports and led by Dr. Lopa Mishra, provides evidence for the role of β2-spectrin in obesity, MASLD, MASH, and HCC. Key points:
- BF-114 targets β2-spectrin and may prevent liver disease progression
- Research strengthens the scientific foundation for BF-114
- BullFrog AI plans to use its AI platform to analyze single-cell data for further insights
- Dr. Mishra joins BullFrog AI's Scientific Advisory Board
The company aims to leverage these findings to advance BF-114's development and explore additional therapeutic applications.
BullFrog AI Holdings (NASDAQ: BFRG; BFRGW), a leader in AI-driven drug discovery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company's CEO, Vin Singh, will deliver a presentation that will be available on demand starting September 9, 2024, at 7:00am ET. Interested parties can access live and archived webcasts of the event through BullFrog AI's investor relations website at investors.bullfrogai.com. This participation provides an opportunity for the company to showcase its advancements in AI-driven drug discovery to a global investment audience.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced significant progress in its collaboration with the Lieber Institute for Brain Development (LIBD) to uncover new insights into bipolar disorder (BD) pathways and potential drug targets. The research has identified specific molecular pathways associated with BD, enabling the discovery of new candidate drug targets.
Key findings include:
- Significant enrichment in 6 out of 68 clusters from the LIBD brain dataset
- Two substantially enriched clusters in the Dentate Gyrus
- One specific cluster associated with BD in the Dorsolateral Prefrontal Cortex
- Potential dysregulation of pro-inflammatory pathways
- Identification of novel pathways significant to BD pathophysiology
BullFrog AI is now focusing on validating these findings in wet lab settings and engaging with pharmaceutical partners to advance these discoveries.
BullFrog AI (NASDAQ: BFRG) is hosting a live investor webinar on June 12, 2024, at 4:15 p.m. ET, featuring insights from CSO Tom Chittenden and LIBD CEO Daniel Weinberger on their collaborative research. The study, using over 2,800 brain samples, has revealed novel insights into psychiatric conditions such as schizophrenia and bipolar disorder through advanced AI techniques. This collaboration has enabled clustering based on biological data, uncovering potential biomarkers and drug targets. The event aims to provide comprehensive details on these findings and discuss future revenue opportunities through potential pharmaceutical partnerships.
BullFrog AI and the Lieber Institute for Brain Development (LIBD) announced significant progress in their collaboration to identify novel drug targets for neuropsychiatric disorders. Using AI and machine learning, they have discovered patient subgroups within conditions like major depression, schizophrenia, and bipolar disorder. This approach led to identifying key genes that present new potential drug targets. BullFrog AI is applying Causal AI to validate these targets, aiming to develop targeted treatments for psychiatric disorders. The collaboration has also started engagements with pharmaceutical companies for strategic partnerships.
BullFrog AI Holdings, Inc. (NASDAQ:BFRG) and GreenPower Motor Company Inc. (NASDAQ:GP) will be featured on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV. Vin Singh, CEO of BullFrog AI, will discuss the company's bfLEAP™ platform revolutionizing drug discovery. Fraser Atkinson, CEO of GreenPower, will highlight the company's success in the electric vehicle market.
